DrugSupplement
Gluconates clinical trials
Also written Copper Gluconate.
- studies test it
- 9
- open now
- 3
- in phase 3
- 0
- first study started
- 2008
Keep track of what changes. Save the Gluconates studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Other names
Combined with it in one product
Studies by the year they started
8 studies that test it; most in 2008 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2008 | 1 |
| 2010 | 1 |
| 2016 | 1 |
| 2018 | 1 |
| 2019 | 1 |
| 2021 | 1 |
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 5
- Phase 2
- 4
- No phase
- 1
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 0 · Other 9
University of Utah (2) · Washington University School of Medicine (1) · M.D. Anderson Cancer Center (1) · Case Comprehensive Cancer Center (1) · University of Washington (1) · Wake Forest University Health Sciences (1) · HonorHealth Research Institute (1) · Purdue University (1)
Often tested with
Tested in the same studies.
Disulfiram (7) · Temozolomide (2) · Radiation Therapy (1) · Liposomal doxorubicin (1) · Doxorubicin (1) · Albumin-Bound Paclitaxel (1) · Paclitaxel (1) · Folfirinox (1)
Studies
Open first, then newest update. How each study uses Gluconates is read from its arms, and is right about nine times in ten.
Testing it · 9
- MINTER Trial: Metal Intervention aNd ThErapy With Radiotherapy In Thoracic Cancer Using Copper Donor Therapy: A Phase 2, Open-Label StudyNot yet recruitingPhase 2M.D. Anderson Cancer CenterNCT07843537Written as Copper Gluconate 2 mg
- Disulfiram With Copper Gluconate and Liposomal Doxorubicin in Treatment-Refractory SarcomasRecruitingPhase 1Case Comprehensive Cancer CenterNCT05210374Written as Copper Gluconate
- Copper Supplementation in CirrhosisRecruitingNot applicableUniversity of WashingtonNCT07471542Written as Copper Gluconate
- Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed GlioblastomaCompletedPhase 1/2Washington University School of MedicineNCT02715609Written as Copper Gluconate
- Disulfiram and Copper Gluconate With Temozolomide in Unmethylated Glioblastoma MultiformeTerminatedPhase 2Wake Forest University Health SciencesNCT03363659Written as Copper gluconate
- Disulfiram-Copper Gluconate in Met Pancreas Cancer w Rising CA19-9 on Abraxane-Gemzar, FOLFIRINOX or GemcitabineTerminatedPhase 2HonorHealth Research InstituteNCT03714555Written as FOLFIRINOX regimen Plus Disulfiram/Copper Gluconate
- Study of Disulfiram and Copper Gluconate in Patients With Treatment-Refractory Multiple MyelomaTerminatedPhase 1University of UtahNCT04521335Written as Copper Gluconate
- Human Biomarkers for Assessing Copper DeficiencyStatus unknownPhase 1Purdue UniversityNCT01177579Written as Copper gluconate
- Phase I Study of Disulfiram and Copper Gluconate for the Treatment of Refractory Solid Tumors Involving the LiverCompletedPhase 1University of UtahNCT00742911Written as Copper Gluconate
Given in every arm · 2 — Gluconates is usual care beside what is tested
- A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate CancerTerminatedPhase 1Daniel George, MDNCT02963051Written as Copper gluconate
- Disulfiram in Treating Patients With Glioblastoma Multiforme After Radiation Therapy With TemozolomideCompletedEarly Phase 1Washington University School of MedicineNCT01907165Written as Copper gluconate
Codes
What other systems call Gluconates · ClinicalTrials.gg INT007560
- MeSH (NLM) D005942GluconatesOne source NLM
- UNII (FDA) RV823G6G67COPPER GLUCONATEConfirmed FDA, NLM
- RxNorm 2839One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D005942 | Gluconates | One source NLM |
| UNII (FDA) | RV823G6G67 | COPPER GLUCONATE | Confirmed FDA, NLM |
| RxNorm | 2839 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.